Browsing by Author "Assi, Rita"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    A nontandem novel compound chimeric antigen receptor redirected to target CD20-CD19 positive B-cell acute leukemias and B-cell lymphoma
    (Wiley, 2024) DeStefano, Vincent M.; Wada, Masayuki; Pinz, Kevin G.; Assi, Rita; Zhang, Hongyu; Wang, Weijia; Zhang, Wenli; Shah, Darshi; Ma, Yupo; Salman, Huda; Medicine, School of Medicine
  • Thumbnail Image
    Item
    Harnessing the Potential of Chimeric Antigen Receptor T-Cell Therapy for the Treatment of T-Cell Malignancies: A Dare or Double Dare?
    (MDPI, 2022-12-08) Assi, Rita; Salman, Huda; Medicine, School of Medicine
    Historical standard of care treatments of T-cell malignancies generally entailed the use of cytotoxic and depleting approaches. These strategies are, however, poorly validated and record dismal long-term outcomes. More recently, the introduction and approval of chimeric antigen receptor (CAR)-T cell therapy has revolutionized the therapy of B-cell malignancies. Translating this success to the T-cell compartment has so far proven hazardous, entangled by risks of fratricide, T-cell aplasia, and product contamination by malignant cells. Several strategies have been utilized to overcome these challenges. These include the targeting of a selective cognate antigen exclusive to T-cells or a subset of T-cells, disruption of target antigen expression on CAR-T constructs, use of safety switches, non-viral transduction, and the introduction of allogeneic compounds and gene editing technologies. We herein overview these historical challenges and revisit the opportunities provided as potential solutions. An in-depth understanding of the tumor microenvironment is required to optimally harness the potential of the immune system to treat T-cell malignancies.